For the optimists, among whom we include ourselves, the glass is half full. Not everyone, like us, lived those days when, in order to treat asthma, we only had theophylline, oral corticosteroids, and short-acting ß 2 agonists for use orally or by nebulization. Those were the days when emergency rooms and wards were crowded with asthma patients. It is indisputable that there have been great advances in knowledge about the pathophysiology of asthma in recent decades, and that, consequently, there has been a remarkable increase in the number of asthma control medications available. However, the benefits of these advances in knowledge do not extend to all in need.
Paradoxically, asthma control remains suboptimal worldwide. (2, 3) In 2011, a survey involving several countries in Latin America interviewed 2,169 adult patients with asthma or parents of children with asthma; only 9% of the Brazilian respondents had controlled asthma. (3) With regard to the past 12 months, 27% of the Brazilian respondents reported having been hospitalized and an additional 47% reported having received emergency room treatment. (4) More recently, study of data from a previous survey (5) of 12,000 Brazilian adults who agreed to complete the study questionnaire showed that 4.1% of the respondents had a previous diagnosis of asthma. Of those, 52.1%, 36.4%, and 12.3% had uncontrolled asthma, partially controlled asthma, and controlled asthma, respectively. Only 32.4% of the respondents reported full adherence to the prescribed treatment regimen. When compared with controls, asthma patients had poorer quality of life and a higher number of hospitalizations in the past 6 months. Work productivity (rates of absenteeism and presenteeism) was lower in asthma patients than in controls. (5) Do these results indicate that the glass is half empty? Yes, as far as asthma control is concerned. Pulmonologists, clinicians, and pediatricians involved in asthma management in Brazil face several challenges that vary in complexity according to local and patient socioeconomic and cultural conditions, patient beliefs and attitudes, the resources available in health care facilities to investigate and confirm the diagnosis of asthma, the level of patient access to the prescribed medications, physician work overload, etc. In addition, asthma is a complex and heterogeneous disease, for which inhaled drug treatment in itself poses a challenge regarding the correct use of inhalers and treatment adherence, as well as regarding the choice of the most appropriate inhaler and the most appropriate dose for a given patient. (6) That said, we should add that the vast majority of asthma patients are found in primary and pediatric care clinics. For this vast majority of asthma patients, treatment is simple, with rapid resolution of symptoms, since asthma is a concordant disease (i.e., the more severe the symptoms are, the more severe is the airway inflammation), which usually responds well to symptom-guided treatment. (7) If most asthma patients have treatment-responsive asthma (7) and can easily control it, then why does asthma control remain suboptimal? In addition to several voluntary and involuntary factors involved in treatment adherence, (6) a plausible possibility is poor physicianpatient communication. (8, 9) As in any chronic disease, the physician-patient relationship cannot be just rhetoric; it should be a reality in which the physician sets aside time to establish trust and bond with the patient. Suboptimal asthma control most likely results from the combination of lack of a tailored approach, both biologically and psychosocially, and lack of detailed knowledge about the behavior of patients, with their expectations and fears, as well as from difficulties in choosing the most appropriate inhaler for each patient. (6, 10) Poor asthma control rates are red flags calling attention to the need for interventions aimed at developing the skills not only of physicians but also of the entire health care team for understanding the complexity of asthma. Asthma does not have a single diagnostic biomarker, and its treatment requires the use of inhalers. However, in most cases, the disease can be controlled very easily by using medications dispensed free of charge under the Brazilian Popular Pharmacy program.
There are also concrete data showing that the glass is half full. In Brazil, longitudinal trends in asthma health care use have shown that, between 2008 and 2014, there was a mean decrease of 43% in the number of asthma-related hospitalizations among patients aged 1 to 49 years, a finding that is consistent with the provision of medications free of charge via the Brazilian Unified Health Care System as of 2008. (11) These data are encouraging but can be greatly improved. In Finland, (12) a program aimed at increasing asthma diagnosis and control that was implemented 27 years ago resulted in a significant reduction in asthma-related costs despite an increase of almost 300% in the number of asthma diagnoses in the same period. Costs per patient decreased by 72%. In addition, the proportion of patients with severe asthma exacerbation decreased from 20% to 2.5%. The success of the program was attributed to the local emphasis, the engagement of all staff involved in asthma management, and the view that asthma is a public health problem whose solution should involve health care professionals and the public through targeted educational campaigns and zero tolerance to underdiagnosis and undertreatment of asthma. (13) It could be argued that Finland is a small, developed country. Several municipal-level experiences in Brazil have shown that the same can successfully be done in our country when there are specialists willing to work in the Brazilian Unified Health Care System to provide referral centers and train primary health care professionals. (14) (15) (16) (17) In conclusion, it is time we stopped looking at the glass and rolled up our sleeves. Let us fill up the glass together. We want a Brazil where everyone can breathe!
